LC
GILD icon

Lavaca Capital’s Gilead Sciences GILD Stock Holding History

Lavaca Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Hold
1,489
– – 0.02% 127
2026
Q1 		$208K Hold
1,489
– – 0.04% 102
2025
Q4 		$183K Hold
1,489
– – 0.03% 105
2025
Q3 		$165K Hold
1,489
– – 0.03% 105
2025
Q2 		$165K Hold
1,489
– – 0.06% 107
2025
Q1 		$167K Hold
1,489
– – 0.07% 108
2024
Q4 		$138K Buy
+1,489
New +$134K 0.05% 126
2019
Q2 		– Sell
-57
Closed -$4K – 187
2019
Q1 		$4K Hold
57
– – ﹤0.01% 336
2018
Q4 		$4K Buy
+57
New +$3.98K ﹤0.01% 302

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lavaca Capital's GILD Position: Q2 2026 in Review

Lavaca Capital held its Gilead Sciences (GILD) position steady in Q2 2026 at 1,489 shares worth $188K. The position accounts for 0.02% of the portfolio, ranked #127.

Lavaca Capital first reported a position in GILD in Q4 2018 and has held it in 9 quarters since. The position peaked at $208K in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Lavaca Capital held 1,489 shares of Gilead Sciences worth $188K as of Q2 2026.
  • Lavaca Capital left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.02% of Lavaca Capital's portfolio in Q2 2026, its #127 holding.
  • Lavaca Capital first reported a position in Gilead Sciences in Q4 2018 and has held it in 9 quarters since.
  • Lavaca Capital's Gilead Sciences position peaked at $208K in Q1 2026.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Lavaca Capital's 13F filing for Q2 2026, filed 14 Aug 2026.